Mitochondrial stress and glycoxidation increase with decreased kidney function.

Mitochondrial stress increases the production of fumarate, an intermediate of the Krebs cycle. Fumarate non-enzymatically reacts with the thiol group of cysteine, leading to the production of -(2-succinyl)cysteine. Here, we quantified the concentration of fumarate, the free form of -(2-succinyl)cysteine, and advanced glycation end-products, including -(carboxymethyl)lysine and -(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine, in the serum of chronic kidney disease patients, using liquid chromatography-tandem mass spectrometry and an enzymatic assay. In a cross-sectional study, we evaluated the difference in metabolite concentration between healthy individuals ( = 22) and kidney transplant patients ( = 93). Additionally, we evaluated the metabolite concentration of end-stage renal disease patients ( = 17) before and 1, 3, 6, and 12 months after transplantation, in a longitudinal study. While the -(2-succinyl)cysteine and AGEs levels were significantly increased in accordance with the rising chronic kidney disease severity, they were significantly decreased after transplantation. However, fumarate levels were only significantly different in end-stage renal disease patients. The -(2-succinyl)cysteine levels correlated with the pre-existing kidney function marker. This study demonstrates that mitochondrial metabolic disorders contribute to impaired kidney function, and that measuring blood -(2-succinyl)cysteine levels may be a minimally invasive way to evaluate the metabolic change in chronic kidney disease.